Overview

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
MedImmune LLC
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide